Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. Social Networks
  11. External Links
  12. Analytics And Tracking
  13. Libraries
  14. Hosting Providers

We began analyzing https://jhoonline.biomedcentral.com/articles/10.1186/s13045-025-01703-4, but it redirected us to https://jhoonline.biomedcentral.com/articles/10.1186/s13045-025-01703-4. The analysis below is for the second page.

Title[redir]:
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs | Journal of Hematology & Oncology | Full Text
Description:
Selective elimination of proteins associated with the pathogenesis of diseases is an emerging therapeutic modality with distinct advantages over traditional inhibitor-based approaches. This strategy, called targeted protein degradation (TPD), is based on hijacking the cellular proteolytic machinery using chimeric degrader molecules that physically link the target protein of interest with the degradation effectors. The TPD era began with the development of PROteolysis TAtrgeting Chimeras (PROTACs) in 2001, with various methods and applications currently available. Classical PROTAC molecules are heterobifunctional chimeras linking target proteins with E3 ubiquitin ligases. This induced interaction leads to the ubiquitylation of the target protein, which is needed for its recognition and subsequent degradation by the cellular proteasomes. However, this technology is limited to intracellular proteins since the effectors involved (E3 ubiquitin ligases and proteasomes) are located in the cytosol. The related methods for selective destruction of proteins present in the extracellular space have only emerged recently and are collectively termed extracellular TPD (eTPD). The prototypic eTPD technology utilizes LYsosomal TArgeting Chimeras (LYTACs) that link extracellular target proteins (secreted or membrane-associated) to lysosome-targeting receptors (LTRs) on the cell surface. The resulting complex is then internalized by endocytosis and trafficked to lysosomes, where the target protein is degraded. The successful elimination of various extracellular proteins via LYTACs and related approaches has been reported, including several important targets in oncology that drive tumor growth and dissemination. This review summarizes current progress in the eTPD field and focuses primarily on the respective technological developments. It discusses the design principles and diversity of degrader molecules and the landscape of available targets and effectors that can be employed for eTPD. Finally, it emphasizes current open questions, challenges, and perspectives of this technological platform to promote the expansion of the eTPD toolkit and further development of its therapeutic applications.

Matching Content Categories {📚}

  • Science
  • Education
  • Fitness & Wellness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌌 Gigantic Traffic: 2M - 5M visitors per month


Based on our best estimate, this website will receive around 4,145,289 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

The income method remains a mystery to us.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Doi.org has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

pubmed, article, degradation, google, scholar, cas, proteins, protein, etpd, degraders, molecules, receptor, degrader, central, targeted, target, cell, chem, targeting, extracellular, chimeras, poi, membrane, ubiquitin, lysosomal, internalization, wang, zhang, approaches, protac, ltrs, ligands, antibodies, small, approach, complex, targets, ltr, tpd, field, design, ligases, protacs, chimera, specific, cancer, study, recent, signaling, endocytosis,

Topics {✒️}

multiple serine-o-mannose-6-phosphonate r-spondin/lgr5/rnf43 module cation-independent mannose-6-phosphate receptor direct endosome/lysosome targeting decrease low-density lipoprotein lysosome-targeting chimeras mediated central signaling hubs lysosome-targeting chimeras evolve e2 ubiquitin-conjugating enzymes degrading pro-inflammatory cytokines dileucine-based peptide sfhddsdedllhi synthetic alpha-helix mimetics dual-targeted proteins degradation polyspecific integrin-binding peptide residue egfr-targeting peptide stem cell-derived cytokines called lysosome-targeting chimeras snca/α-synuclein aggregates single-pass membrane protein stem-cell e3 ligase passive tumour-targeting strategies igf2r/ci-m6pr-based degraders full size image lysosome-targeting protein degradation triantennary n-acetylgalactosamine conjugates mannose 6-phosphate/igf2 receptor tested peptide-based signaltacs computer-assisted protac design unlike endocytosis-related pathways dcaf16-based covalent handle effective atg8-based attecs computer-aided degrader design central nervous system undergo clathrin-mediated endocytosis specifically recognizing ci-m6pr designing tissue-specific degraders resembling α-helical peptides promote tissue-specific regeneration includes antibody-based ligands membrane-localized target protein site-specific chemoenzymatic conjugation glycine-based internalization motif direct endocytosis-dependent methods durable pd-l1 degradation htt-lc3 linker compounds natural high-affinity ligand classical lytac-related etpd cell surface-located proteins cd24/siglec-10 signaling pathway site-specific antibody conjugation

Questions {❓}

  • Targeted protein degradation: the new frontier of antimicrobial discovery?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs
         description:Selective elimination of proteins associated with the pathogenesis of diseases is an emerging therapeutic modality with distinct advantages over traditional inhibitor-based approaches. This strategy, called targeted protein degradation (TPD), is based on hijacking the cellular proteolytic machinery using chimeric degrader molecules that physically link the target protein of interest with the degradation effectors. The TPD era began with the development of PROteolysis TAtrgeting Chimeras (PROTACs) in 2001, with various methods and applications currently available. Classical PROTAC molecules are heterobifunctional chimeras linking target proteins with E3 ubiquitin ligases. This induced interaction leads to the ubiquitylation of the target protein, which is needed for its recognition and subsequent degradation by the cellular proteasomes. However, this technology is limited to intracellular proteins since the effectors involved (E3 ubiquitin ligases and proteasomes) are located in the cytosol. The related methods for selective destruction of proteins present in the extracellular space have only emerged recently and are collectively termed extracellular TPD (eTPD). The prototypic eTPD technology utilizes LYsosomal TArgeting Chimeras (LYTACs) that link extracellular target proteins (secreted or membrane-associated) to lysosome-targeting receptors (LTRs) on the cell surface. The resulting complex is then internalized by endocytosis and trafficked to lysosomes, where the target protein is degraded. The successful elimination of various extracellular proteins via LYTACs and related approaches has been reported, including several important targets in oncology that drive tumor growth and dissemination. This review summarizes current progress in the eTPD field and focuses primarily on the respective technological developments. It discusses the design principles and diversity of degrader molecules and the landscape of available targets and effectors that can be employed for eTPD. Finally, it emphasizes current open questions, challenges, and perspectives of this technological platform to promote the expansion of the eTPD toolkit and further development of its therapeutic applications.
         datePublished:2025-05-01T00:00:00Z
         dateModified:2025-05-01T00:00:00Z
         pageStart:1
         pageEnd:21
         license:http://creativecommons.org/licenses/by-nc-nd/4.0/
         sameAs:https://doi.org/10.1186/s13045-025-01703-4
         keywords:
            Targeted protein degradation
            LYTAC
            PROTAC
            Secreted proteins
            Membrane proteins
            Oncology
            Hematology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-025-01703-4/MediaObjects/13045_2025_1703_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-025-01703-4/MediaObjects/13045_2025_1703_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-025-01703-4/MediaObjects/13045_2025_1703_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-025-01703-4/MediaObjects/13045_2025_1703_Fig4_HTML.png
         isPartOf:
            name:Journal of Hematology & Oncology
            issn:
               1756-8722
            volumeNumber:18
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:M. A. A. Mamun
               affiliation:
                     name:Taizhou University
                     address:
                        name:School of Medicine, Taizhou University, Taizhou, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Anush G. Bakunts
               affiliation:
                     name:Vita-Salute San Raffaele University
                     address:
                        name:Division of Genetics and Cell Biology, Vita-Salute San Raffaele University, Milan, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alexander L. Chernorudskiy
               affiliation:
                     name:Taizhou University
                     address:
                        name:School of Medicine, Taizhou University, Taizhou, People’s Republic of China
                        type:PostalAddress
                     type:Organization
                     name:Mario Negri Institute for Pharmacological Research
                     address:
                        name:Department of Biochemistry and Molecular Pharmacology, Mario Negri Institute for Pharmacological Research, Milan, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs
      description:Selective elimination of proteins associated with the pathogenesis of diseases is an emerging therapeutic modality with distinct advantages over traditional inhibitor-based approaches. This strategy, called targeted protein degradation (TPD), is based on hijacking the cellular proteolytic machinery using chimeric degrader molecules that physically link the target protein of interest with the degradation effectors. The TPD era began with the development of PROteolysis TAtrgeting Chimeras (PROTACs) in 2001, with various methods and applications currently available. Classical PROTAC molecules are heterobifunctional chimeras linking target proteins with E3 ubiquitin ligases. This induced interaction leads to the ubiquitylation of the target protein, which is needed for its recognition and subsequent degradation by the cellular proteasomes. However, this technology is limited to intracellular proteins since the effectors involved (E3 ubiquitin ligases and proteasomes) are located in the cytosol. The related methods for selective destruction of proteins present in the extracellular space have only emerged recently and are collectively termed extracellular TPD (eTPD). The prototypic eTPD technology utilizes LYsosomal TArgeting Chimeras (LYTACs) that link extracellular target proteins (secreted or membrane-associated) to lysosome-targeting receptors (LTRs) on the cell surface. The resulting complex is then internalized by endocytosis and trafficked to lysosomes, where the target protein is degraded. The successful elimination of various extracellular proteins via LYTACs and related approaches has been reported, including several important targets in oncology that drive tumor growth and dissemination. This review summarizes current progress in the eTPD field and focuses primarily on the respective technological developments. It discusses the design principles and diversity of degrader molecules and the landscape of available targets and effectors that can be employed for eTPD. Finally, it emphasizes current open questions, challenges, and perspectives of this technological platform to promote the expansion of the eTPD toolkit and further development of its therapeutic applications.
      datePublished:2025-05-01T00:00:00Z
      dateModified:2025-05-01T00:00:00Z
      pageStart:1
      pageEnd:21
      license:http://creativecommons.org/licenses/by-nc-nd/4.0/
      sameAs:https://doi.org/10.1186/s13045-025-01703-4
      keywords:
         Targeted protein degradation
         LYTAC
         PROTAC
         Secreted proteins
         Membrane proteins
         Oncology
         Hematology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-025-01703-4/MediaObjects/13045_2025_1703_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-025-01703-4/MediaObjects/13045_2025_1703_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-025-01703-4/MediaObjects/13045_2025_1703_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-025-01703-4/MediaObjects/13045_2025_1703_Fig4_HTML.png
      isPartOf:
         name:Journal of Hematology & Oncology
         issn:
            1756-8722
         volumeNumber:18
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:M. A. A. Mamun
            affiliation:
                  name:Taizhou University
                  address:
                     name:School of Medicine, Taizhou University, Taizhou, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anush G. Bakunts
            affiliation:
                  name:Vita-Salute San Raffaele University
                  address:
                     name:Division of Genetics and Cell Biology, Vita-Salute San Raffaele University, Milan, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alexander L. Chernorudskiy
            affiliation:
                  name:Taizhou University
                  address:
                     name:School of Medicine, Taizhou University, Taizhou, People’s Republic of China
                     type:PostalAddress
                  type:Organization
                  name:Mario Negri Institute for Pharmacological Research
                  address:
                     name:Department of Biochemistry and Molecular Pharmacology, Mario Negri Institute for Pharmacological Research, Milan, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Hematology & Oncology
      issn:
         1756-8722
      volumeNumber:18
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Taizhou University
      address:
         name:School of Medicine, Taizhou University, Taizhou, People’s Republic of China
         type:PostalAddress
      name:Vita-Salute San Raffaele University
      address:
         name:Division of Genetics and Cell Biology, Vita-Salute San Raffaele University, Milan, Italy
         type:PostalAddress
      name:Taizhou University
      address:
         name:School of Medicine, Taizhou University, Taizhou, People’s Republic of China
         type:PostalAddress
      name:Mario Negri Institute for Pharmacological Research
      address:
         name:Department of Biochemistry and Molecular Pharmacology, Mario Negri Institute for Pharmacological Research, Milan, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:M. A. A. Mamun
      affiliation:
            name:Taizhou University
            address:
               name:School of Medicine, Taizhou University, Taizhou, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Anush G. Bakunts
      affiliation:
            name:Vita-Salute San Raffaele University
            address:
               name:Division of Genetics and Cell Biology, Vita-Salute San Raffaele University, Milan, Italy
               type:PostalAddress
            type:Organization
      name:Alexander L. Chernorudskiy
      affiliation:
            name:Taizhou University
            address:
               name:School of Medicine, Taizhou University, Taizhou, People’s Republic of China
               type:PostalAddress
            type:Organization
            name:Mario Negri Institute for Pharmacological Research
            address:
               name:Department of Biochemistry and Molecular Pharmacology, Mario Negri Institute for Pharmacological Research, Milan, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:School of Medicine, Taizhou University, Taizhou, People’s Republic of China
      name:Division of Genetics and Cell Biology, Vita-Salute San Raffaele University, Milan, Italy
      name:School of Medicine, Taizhou University, Taizhou, People’s Republic of China
      name:Department of Biochemistry and Molecular Pharmacology, Mario Negri Institute for Pharmacological Research, Milan, Italy

Social Networks {👍}(2)

External Links {🔗}(624)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com
5.07s.